Opioid Induced Constipation Clinical Trial
Official title:
An Observational Post-Authorization Safety Study (PASS) of MOVENTIG® (Naloxegol) Drug Utilization in Selected European Populations
This post-authorization observational safety study determines the characteristics of patients prescribed naloxegol at time of first prescription and treatment patterns of naloxegol in follow-up in the United Kingdom (UK), Norway, Sweden, and Germany.
The overall research questions for this study are: 1) What are the demographic, clinical, and treatment characteristics (including dose) at baseline of patients prescribed naloxegol in real-world practice (including the use of naloxegol in non-indicated populations)? and 2) What are the treatment patterns of naloxegol utilization during follow-up? Primary objectives: 1. To describe the characteristics of patients prescribed naloxegol at time of first prescription (demographics, targeted comorbidities, targeted comedications, provider characteristics, and indication characteristics). 2. To describe any of the following treatment patterns: - Discontinuation of naloxegol (permanently during the observation period) - Switching from naloxegol to other drug(s) potentially used by patients with opioid induced constipation (OIC) - Prescription of other drug(s) potentially used by patients with OIC in the same period when naloxegol is prescribed (augmentation) - Restart in the prescription of naloxegol (after temporary discontinuation or treatment holiday) - Continuous treatment with naloxegol during the study period - Change in dosing Exploratory objective: 1. To identify predictors of length of naloxegol use ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02813369 -
Naloxegol Health Outcome Post Authorisation Safety Study
|
||
| Completed |
NCT01957046 -
A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC).
|
Phase 4 | |
| Completed |
NCT01401985 -
A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
|
Phase 2 | |
| Completed |
NCT00984334 -
Naloxone SR Capsules in Patients With Opioid Induced Constipation
|
Phase 2 | |
| Completed |
NCT01207427 -
Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
|
Phase 2 | |
| Completed |
NCT01459926 -
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation
|
Phase 2 | |
| Terminated |
NCT01117051 -
Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation
|
Phase 3 | |
| Completed |
NCT03060512 -
To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
|
Phase 4 | |
| Completed |
NCT01109511 -
A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy
|
Phase 4 | |
| Active, not recruiting |
NCT02813356 -
Naloxegol US PMR CV Safety.
|
||
| Completed |
NCT01812733 -
Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives
|
N/A | |
| Completed |
NCT01623609 -
Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol
|
Phase 1 | |
| Completed |
NCT01443403 -
A Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy
|
Phase 2 | |
| Completed |
NCT03638440 -
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.
|